TransCode Therapeutics (RNAZ) Stock Price, Quote, News & History | Benzinga

TransCode Therapeutics Inc (RNAZ) Stock Price, Quote, News & History

RNAZNASDAQ

Trade with Public

Trade with Public

$6.18

0.00780.13%

At close: May 19, 5:00 PM EST

$6.25

0.07211.17%

After Hours: 9:29 AM EST

Earnings: Q1 2026 Earnings were released on Fri May 15th, after the market close

OverviewNews Earnings Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$6.35

Close

$6.18

Volume / Avg.

11.61K / 9.90K

Day Range

$6.01 - $6.50

52 Wk Range

6.02 - 20.99

Market Cap

$5.73M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

23

Short Interest

3.9%

Days to Cover

7.56

Recent Transcode Therapeutics Inc News

TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout

TransCode Therapeutics Inc. (NASDAQ: RNAZ) to acquire Polynoma LLC and receive $25 million investment from CK Life Sciences.

Triveni Kothapalli

EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug

TransCode Therapeutics advances Phase 1a trial of TTX-MC138 for metastatic cancer with early signs of stability and consistent PK/PD data.

Vandana Singh

TransCode Therapeutics Shares Are Surging Today: What's Going On?

TransCode Therapeutics Inc. (NASDAQ: RNAZ) shares are moving higher Friday after the company announced that the first patient in Cohort 3 of its Phase 1 clinical trial has been dosed with its lead candidate, TTX-MC138 on Tuesday.

Vaishali Prayag

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-19.52M

Investing Cash Flow (TTM)

-4.44K

Financing Cash Flow (TTM)

31.52M

Free Cash Flow (TTM)

-19.52M

Capital Expenditure (TTM)

-6.66K

Net Change in Cash (TTM)

12.00M

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$114.99K

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

0.55

Earnings Yield % (TTM)

-852.34%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$11.27

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$17.81M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$6.35

Close

$6.18

Volume / Avg.

11.61K / 9.90K

Day Range

$6.01 - $6.50

52 Wk Range

6.02 - 20.99

Market Cap

$5.73M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

23

Short Interest

3.9%

Days to Cover

7.56

About

Sector

Health Care

Industry

Biotechnology

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Pha...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy TransCode Therapeutics (RNAZ) stock?

A

You can purchase shares of TransCode Therapeutics (NASDAQ:RNAZ) through any online brokerage.

View our list of the best stock brokerages

Q

Who are TransCode Therapeutics (RNAZ) competitors?

A

There are no as such competitors for TransCode Therapeutics.

Q

What is the forecast, or price target, for TransCode Therapeutics (RNAZ) stock?

A

TransCode Therapeutics has a consensus price target of $10.00.

Q

What is the current price for TransCode Therapeutics (RNAZ)?

A

The stock price for TransCode Therapeutics (NASDAQ: RNAZ) is $6.25 last updated May 19, 2026 at 9:29 AM EDT.

Q

Does TransCode Therapeutics (RNAZ) pay a dividend?

A

There are no upcoming dividends for TransCode Therapeutics.

Q

When is TransCode Therapeutics (NASDAQ:RNAZ) reporting earnings?

A

TransCode Therapeutics does not have any upcoming earnings scheduled.

Q

Is TransCode Therapeutics (RNAZ) going to split?

A

There is no upcoming split for TransCode Therapeutics.

Q

What sector and industry does TransCode Therapeutics (RNAZ) operate in?

A

TransCode Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.